Myndlift News
7 articles
Interaxon Inc. (Muse®) Highlights Myndlift's Preliminary Study and the Benefit of Partnerships for Digital Therapeutics Research
Myndlift, a health technology company that uses Muses EEG technology platform, has completed a study showing the preliminary efficacy of remote neurofeedback therapy (NFT) on improved mental health outcomes. The study involved 593 participants and focused on disorders such as ADHD, anxiety, and depression. The results showed reduced symptom severity and adjusted resting EEG neural markers for individuals with symptoms of ADHD. Myndlifts combination of traditional neurofeedback, CBT tools, and coaching aims to improve access to mental health tools that can remotely support the general focus and wellbeing of patients with these disorders as a low-cost alternative to clinic-based EEG.
PartnersCustomers
Myndlift Publishes Study Showing Evidence Supporting the Efficacy of a Remote Neurofeedback System in Improving Mental Health
Myndlift, a leading provider of therapist-guided remote neurotherapy, published a study demonstrating the efficacy of their remote neurofeedback system in improving mental health. The study showed positive outcomes in reducing symptoms of ADHD, depression, and anxiety, as well as improving attention, cognitive performance, and executive function. The study evaluated Myndlifts model with 560 subjects and found that over 50% of participants demonstrated clinically significant improvement. The results surpassed those of other in-app mental health services. Myndlift aims to make neurofeedback accessible and affordable to help the millions of people struggling with mental health disorders. They partner with leaders in the neurotherapy and behavioral therapy fields to expand their offering. The study was published in JMIR Publications.
Customers
The Israeli startup making neurofeedback accessible for everyone Startups Magazine
Myndlift, a neurofeedback startup, is revolutionizing the treatment of common mental health conditions by providing an affordable and accessible therapy option. The companys app allows users to retrain their brains through gaming, using a neurofeedback headset and EEG electrodes. Positive visual and audio feedback is used to encourage optimal mental states, helping users stay focused and calm. Myndlift aims to make neurofeedback therapy the next frontier of mental health technology, providing tangible progress and information to improve mental wellbeing. The companys growth prospects are positive as it addresses the increasing demand for alternative mental health treatments.
CustomersExpand
Israeli app offers alternative to hyperactivity medications
Myndlift, a brain-tech startup, is using neurofeedback to provide an alternative non-drug treatment for attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). The company offers a mobile app and wearable technology that train the brain to focus and improve attention levels. Myndlift aims to disrupt the current treatment for ADD and ADHD and impact the wider healthcare market. The founders, Aziz Kaddan and Anas Abu Mukh, believe that their product can replace medications like Ritalin and provide a more accessible and affordable solution. Myndlift has already gained recognition and interest from medical innovation leaders and brain-technology conferences. The company is currently focused on R&D and developing their mobile apps and adding new games to their platform.
Customers
A start-up making play for billions in ADHD drug market
Myndlift, a technology company founded by Aziz Kaddan, aims to help people with ADHD by providing a drug-free solution to improve concentration and focus. The company uses neurofeedback technology, which measures brain activity through a headset and sends the data to a mobile app. Myndlift plans to enter the U.S. market through its affiliation with ICONYC Labs and expects to release the product in early 2016. The ADHD therapeutics market is growing, with global revenue expected to reach $9.4 billion by 2020. Myndlift does not require FDA approval for its current technology, but plans to go through the regulatory process for future products. Shire is the dominant player in the ADHD market, with its drug Vyvanse generating over $1 billion in sales in 2014.
Customers
Israeli app offers alternative to hyperactivity medications
Myndlift, a brain-tech startup, is developing an alternative non-drug treatment for attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) using neurofeedback. The company aims to help individuals with hyperactivity improve their concentration abilities without prescription drugs by using a mobile app and brain-sensing wearable technology. Myndlifts solution is affordable, accessible, and safe, making it a disruptive force in the current treatment for attention deficit disorders. The founders believe that their medical technology will have a positive impact on the wider healthcare market. Myndlift has already gained recognition and interest from medical innovation leaders and brain-technology conferences. The company is focused on R&D and developing iOS and Android apps, as well as adding new games to their platform.
Customers
Myndlift: An Israeli app being developed to treat ADHD
Myndlift, a start-up founded by Aziz Kaddan and Anas Abu Mukh, aims to provide an alternative treatment for ADHD using a mobile app and neuro-feedback. The app uses a portable EEG device to read brainwaves and offers various activities to improve concentration. The basic app is free, with a premium version available for a monthly or yearly fee. Myndlift participated in the MassChallenge accelerator in Boston and the Y Combinator accelerator in Silicon Valley. The company is seeking investment to further develop the app and potentially treat other disorders such as depression and Alzheimers. Myndlifts founders believe that their product has the potential to replace existing treatment methods and make ADHD treatment more accessible.
Customers